Under terms of the agreement announced Wednesday, Organon could pay out as much as $1.2 billion for Dermavant, a subsidiary of Roivant Sciences. But Roivant is getting just $175 million up front ...
Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is ...
Some results have been hidden because they may be inaccessible to you